G
Gabriel N. Hortobagyi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1415
Citations - 115570
Gabriel N. Hortobagyi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 166, co-authored 1374 publications receiving 104845 citations. Previous affiliations of Gabriel N. Hortobagyi include University of Texas System & University of Texas Medical Branch.
Papers
More filters
Journal ArticleDOI
Survival differences among women with de novo stage IV and relapsed breast cancer
Shaheenah Dawood,Shaheenah Dawood,Kristine Broglio,Joe Ensor,Gabriel N. Hortobagyi,Sharon H. Giordano +5 more
TL;DR: This large cohort study provides further insight into the natural history of relapsed and de novo stage IV breast cancer and plays an important role in the prognosis for patients with relapsed breast cancer.
Journal ArticleDOI
Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma.
TL;DR: The clinical, mammographic, and histologic responses were analyzed after three cycles of preoperative vincristine, doxorubicin, cyclophosphamide, and prednisone that were administered to 143 patients with locally advanced breast cancer.
Journal ArticleDOI
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression.
Qingsong Hu,Youqiong Ye,Li Chuan Chan,Yajuan Li,Ke Liang,Aifu Lin,Aifu Lin,Sergey D. Egranov,Yaohua Zhang,Weiya Xia,Jing Gong,Yinghong Pan,Sujash S. Chatterjee,Jun Yao,Kurt W. Evans,Tina K. Nguyen,Peter K. Park,Jiewei Liu,Cristian Coarfa,Sri Ramya Donepudi,Vasanta Putluri,Nagireddy Putluri,Arun Sreekumar,Chandrashekar R. Ambati,David H. Hawke,Jeffrey R. Marks,Preethi H. Gunaratne,Preethi H. Gunaratne,Abigail S. Caudle,Aysegul A. Sahin,Gabriel N. Hortobagyi,Funda Meric-Bernstam,Lieping Chen,Dihua Yu,Mien Chie Hung,Michael A. Curran,Leng Han,Chunru Lin,Liuqing Yang +38 more
TL;DR: LncRNA-dependent downregulation of antigenicity and intrinsic tumor suppression is demonstrated, which provides the basis for developing combinational immunotherapy treatment regimens and early TNBC prevention.
Journal ArticleDOI
Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: A randomized clinical trial
Simona F. Shaitelman,Pamela J. Schlembach,Isidora Arzu,Matthew T. Ballo,Elizabeth S. Bloom,Daniel Buchholz,Gregory M. Chronowski,Tomas Dvorak,Emily Grade,Karen E. Hoffman,Patrick J. Kelly,Michelle Ludwig,George H. Perkins,Valerie Klairisa Reed,Shalin J. Shah,Michael C. Stauder,Eric A. Strom,Welela Tereffe,Wendy A. Woodward,Joe Ensor,Donald P. Baumann,Alastair M. Thompson,Diana N Amaya,Tanisha Davis,William Guerra,Lois Hamblin,Gabriel N. Hortobagyi,Kelly K. Hunt,Thomas A. Buchholz,Benjamin Smith +29 more
TL;DR: Treating women 40 years or older with stage 0 to II breast cancer with HF-WBI appears to yield lower rates of acute toxic effects and quality of life problems and six months after irradiation, as well as less fatigue and less trouble meeting family needs after completing radiation therapy.
Journal ArticleDOI
Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma.
Massimo Cristofanilli,Yuko Yamamura,Shu Wan Kau,Therese B. Bevers,Sara S. Strom,Modesto Patangan,Limin Hsu,Savitri Krishnamurthy,Richard L. Theriault,Gabriel N. Hortobagyi +9 more
TL;DR: To investigate the role of primary hypothyroidism (HYPT) on breast carcinogenesis, the authors evaluated the association between HYPT and a diagnosis of invasive breast carcinoma and the clinicopathologic characteristics of breast carcinomas in patients with HYPT.